AstraZeneca to Shut Bengaluru Facility

Published: 04th December 2015 04:14 AM  |   Last Updated: 04th December 2015 04:14 AM   |  A+A-

BENGALURU: AstraZeneca Pharma India Ltd on Thursday informed the BSE that its board has decided to close the Active Pharmaceutical Ingredient Unit (API Unit) located at Yelahanka in Bengaluru, citing low demand for the product in the export markets.

The company, however, did not disclose what it intended to do with the employees at the unit.

The company was unavailable for its comments.

"The board took the decision as Terbutaline Sulphate (TBS) was the last API to be manufactured at the API unit and no other API manufacturing activity is planned to be carried out at this unit in the future," it added.

The decision was taken following an application to the Drug Controller General of India (DCGI) to withdraw the manufacturing licence for TBS, AstraZeneca said. The company’s tablet manufacturing plant that started commercial operations in 2013 will continue to operate at the said location, said sources.

Shares of AstraZeneca Pharma India on Thursday closed down 1.57 per cent at `1,107 per share on the BSE,from its previous close.


Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on are those of the comment writers alone. They do not represent the views or opinions of or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp